[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607148":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":30,"responsibleParty":33,"collaborators":30,"id":35,"slug":30,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":30,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":30,"enrollmentInfo":43,"targetDuration":30,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":30,"overallStatus":52,"whyStopped":30,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":30},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Induction Therapy","EXPERIMENTAL","Patients were treated by G-Pola-GemOx as Induction Therapy",[13],"Drug: Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy","Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg\u002Fkg iv qd d1), Gemcitabine (1000 mg\u002Fm2 iv qd d2), Oxaliplatin (100 mg\u002Fm2 iv qd d2) as induction therapy.",[9],[21],"G-Pola-GemOx",[23],{"name":24,"affiliation":5,"role":25},"Liren Qian","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","+861066947194",null,"qlr2007@126.com",{"name":24,"role":28,"phone":30,"phoneExt":30,"email":30},{"type":25,"investigatorFullName":24,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Associate Chief Physician, Associate Professor","100607148",false,"NCT07184788","G-Pola-GemOx in Refractory\u002FRelapsed Aggressive B-Cell Lymphoma","Glofitamab，Polatuzumab Vedotin and GemOx in Refractory\u002FRelapsed Aggressive B-Cell Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Aggressive B-Cell Lymphoma (Including but not limited to diffuse large B-cell lymphoma, mantle cell lymphoma, Burkitt lymphoma, high-grade B-cell lymphoma, etc. according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Patient has not received chemotherapy previously.\n* Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women","ALL","14 Years",{"count":44,"type":45},80,"ESTIMATED","INTERVENTIONAL",[48],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory\u002FRelapsed Aggressive B-Cell Lymphoma.",[51],"Aggressive B-Cell Lymphoma","NOT_YET_RECRUITING","2025-09-14",{"date":55,"type":56},"2025-09-22","ACTUAL",{"date":58,"type":45},"2025-10-01",{"date":60,"type":45},"2031-10-01",{"name":5,"class":6}]